Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALIROCUMAB

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for alirocumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01266876 Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia Completed Sanofi Phase 2 2011-01-01 The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
NCT01266876 Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia Completed Regeneron Pharmaceuticals Phase 2 2011-01-01 The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
NCT01288443 Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy Completed Regeneron Pharmaceuticals Phase 2 2011-01-01 Primary Objective: - To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) on ongoing stable atorvastatin therapy. Secondary Objectives: - To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment in comparison with placebo - To evaluate the safety and tolerability of alirocumab - To evaluate the development of anti-alirocumab antibodies - To evaluate the pharmacokinetics of alirocumab
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for alirocumab

Condition Name

Condition Name for alirocumab
Intervention Trials
Hypercholesterolemia 36
Hypercholesterolaemia 6
Atherosclerosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for alirocumab
Intervention Trials
Hypercholesterolemia 46
Hyperlipoproteinemia Type II 12
Atherosclerosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for alirocumab

Trials by Country

Trials by Country for alirocumab
Location Trials
United States 395
United Kingdom 35
Canada 25
France 16
Israel 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for alirocumab
Location Trials
California 21
Florida 19
Texas 19
Ohio 18
New York 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for alirocumab

Clinical Trial Phase

Clinical Trial Phase for alirocumab
Clinical Trial Phase Trials
Phase 4 12
Phase 3 29
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for alirocumab
Clinical Trial Phase Trials
Completed 26
Recruiting 17
Not yet recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for alirocumab

Sponsor Name

Sponsor Name for alirocumab
Sponsor Trials
Regeneron Pharmaceuticals 52
Sanofi 46
Cambridge University Hospitals NHS Foundation Trust 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for alirocumab
Sponsor Trials
Industry 101
Other 27
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Harvard Business School
Medtronic
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.